vs

Side-by-side financial comparison of ALEXANDERS INC (ALX) and InfuSystem Holdings, Inc (INFU). Click either name above to swap in a different company.

ALEXANDERS INC is the larger business by last-quarter revenue ($53.3M vs $36.2M, roughly 1.5× InfuSystem Holdings, Inc). On growth, InfuSystem Holdings, Inc posted the faster year-over-year revenue change (7.0% vs -4.7%). Over the past eight quarters, InfuSystem Holdings, Inc's revenue compounded faster (6.4% CAGR vs -6.9%).

Alexander's, Inc. is a real estate investment trust that owns 7 properties in New York metropolitan area, including 731 Lexington Avenue, the headquarters of Bloomberg L.P. It is controlled by Vornado Realty Trust. It was founded by George Farkas and Louis Schwadron in 1928.

InfuSystem Holdings, Inc. is a U.S.-headquartered healthcare provider specializing in infusion therapy solutions. It supplies programmable infusion pumps, matching disposable medical consumables, and professional clinical support services, serving oncology clinics, home healthcare providers, and acute care facilities across North America.

ALX vs INFU — Head-to-Head

Bigger by revenue
ALX
ALX
1.5× larger
ALX
$53.3M
$36.2M
INFU
Growing faster (revenue YoY)
INFU
INFU
+11.8% gap
INFU
7.0%
-4.7%
ALX
Faster 2-yr revenue CAGR
INFU
INFU
Annualised
INFU
6.4%
-6.9%
ALX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALX
ALX
INFU
INFU
Revenue
$53.3M
$36.2M
Net Profit
Gross Margin
56.4%
Operating Margin
10.3%
Net Margin
Revenue YoY
-4.7%
7.0%
Net Profit YoY
EPS (diluted)
$0.75
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALX
ALX
INFU
INFU
Q4 25
$53.3M
$36.2M
Q3 25
$53.4M
$36.5M
Q2 25
$51.6M
$36.0M
Q1 25
$54.9M
$34.7M
Q4 24
$55.9M
$33.8M
Q3 24
$55.7M
$35.3M
Q2 24
$53.4M
$33.7M
Q1 24
$61.4M
$32.0M
Net Profit
ALX
ALX
INFU
INFU
Q4 25
Q3 25
$6.0M
$2.3M
Q2 25
$6.1M
$2.6M
Q1 25
$12.3M
$-267.0K
Q4 24
Q3 24
$6.7M
$1.8M
Q2 24
$8.4M
$717.0K
Q1 24
$16.1M
$-1.1M
Gross Margin
ALX
ALX
INFU
INFU
Q4 25
56.4%
Q3 25
57.1%
Q2 25
55.2%
Q1 25
55.2%
Q4 24
53.8%
Q3 24
53.9%
Q2 24
49.5%
Q1 24
51.5%
Operating Margin
ALX
ALX
INFU
INFU
Q4 25
10.3%
Q3 25
10.4%
Q2 25
10.5%
Q1 25
1.8%
Q4 24
7.7%
Q3 24
9.2%
Q2 24
5.5%
Q1 24
-2.6%
Net Margin
ALX
ALX
INFU
INFU
Q4 25
Q3 25
11.2%
6.2%
Q2 25
11.9%
7.2%
Q1 25
22.4%
-0.8%
Q4 24
Q3 24
12.0%
5.1%
Q2 24
15.7%
2.1%
Q1 24
26.2%
-3.5%
EPS (diluted)
ALX
ALX
INFU
INFU
Q4 25
$0.75
$0.09
Q3 25
$1.16
$0.11
Q2 25
$1.19
$0.12
Q1 25
$2.40
$-0.01
Q4 24
$2.39
$0.05
Q3 24
$1.30
$0.08
Q2 24
$1.63
$0.03
Q1 24
$3.14
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALX
ALX
INFU
INFU
Cash + ST InvestmentsLiquidity on hand
$128.2M
$3.2M
Total DebtLower is stronger
$19.6M
Stockholders' EquityBook value
$109.2M
$57.3M
Total Assets
$1.1B
$100.6M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALX
ALX
INFU
INFU
Q4 25
$128.2M
$3.2M
Q3 25
$286.1M
$955.0K
Q2 25
$313.0M
$720.0K
Q1 25
$319.9M
$1.5M
Q4 24
$338.5M
$527.0K
Q3 24
$354.8M
$380.0K
Q2 24
$410.9M
$146.0K
Q1 24
$526.3M
$822.0K
Total Debt
ALX
ALX
INFU
INFU
Q4 25
$19.6M
Q3 25
$20.9M
Q2 25
$26.3M
Q1 25
$28.7M
Q4 24
$23.9M
Q3 24
$28.0M
Q2 24
$34.2M
Q1 24
$29.9M
Stockholders' Equity
ALX
ALX
INFU
INFU
Q4 25
$109.2M
$57.3M
Q3 25
$128.3M
$55.5M
Q2 25
$145.4M
$54.5M
Q1 25
$163.1M
$55.1M
Q4 24
$176.9M
$57.5M
Q3 24
$190.7M
$55.5M
Q2 24
$212.5M
$53.5M
Q1 24
$230.1M
$52.3M
Total Assets
ALX
ALX
INFU
INFU
Q4 25
$1.1B
$100.6M
Q3 25
$1.3B
$98.9M
Q2 25
$1.3B
$100.8M
Q1 25
$1.3B
$104.3M
Q4 24
$1.3B
$103.6M
Q3 24
$1.4B
$105.3M
Q2 24
$1.5B
$108.5M
Q1 24
$1.4B
$104.8M
Debt / Equity
ALX
ALX
INFU
INFU
Q4 25
0.34×
Q3 25
0.38×
Q2 25
0.48×
Q1 25
0.52×
Q4 24
0.41×
Q3 24
0.50×
Q2 24
0.64×
Q1 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALX
ALX
INFU
INFU
Operating Cash FlowLast quarter
$73.4M
$7.1M
Free Cash FlowOCF − Capex
$7.0M
FCF MarginFCF / Revenue
19.3%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$23.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALX
ALX
INFU
INFU
Q4 25
$73.4M
$7.1M
Q3 25
$-9.3M
$8.5M
Q2 25
$43.6M
$7.0M
Q1 25
$15.7M
$1.8M
Q4 24
$54.1M
$7.9M
Q3 24
$-5.0M
$9.8M
Q2 24
$11.5M
$2.3M
Q1 24
$16.8M
$377.0K
Free Cash Flow
ALX
ALX
INFU
INFU
Q4 25
$7.0M
Q3 25
$8.4M
Q2 25
$6.8M
Q1 25
$1.6M
Q4 24
$7.4M
Q3 24
$9.8M
Q2 24
$2.0M
Q1 24
$195.0K
FCF Margin
ALX
ALX
INFU
INFU
Q4 25
19.3%
Q3 25
23.1%
Q2 25
18.9%
Q1 25
4.7%
Q4 24
21.9%
Q3 24
27.7%
Q2 24
5.9%
Q1 24
0.6%
Capex Intensity
ALX
ALX
INFU
INFU
Q4 25
0.4%
Q3 25
0.2%
Q2 25
0.6%
Q1 25
0.4%
Q4 24
1.6%
Q3 24
0.1%
Q2 24
1.0%
Q1 24
0.6%
Cash Conversion
ALX
ALX
INFU
INFU
Q4 25
Q3 25
-1.55×
3.76×
Q2 25
7.12×
2.70×
Q1 25
1.28×
Q4 24
Q3 24
-0.75×
5.45×
Q2 24
1.37×
3.22×
Q1 24
1.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALX
ALX

Segment breakdown not available.

INFU
INFU

Patient Services$20.0M55%
Device Solutions$14.4M40%
Other$1.9M5%

Related Comparisons